• Oversubscribed $1.6 million placement to accelerate U.S. expansion
• Funds to be used for inventory build, sales/marketing, and working capital
• Positions company to scale rapidly expanding U.S. wholesale operations

The Calmer Co International Limited (ASX: CCO) has announced the successful completion of a $1.6 million placement to sophisticated and professional investors. The placement was well supported by new and existing institutional and sophisticated investors and was managed by Novus Capital Limited as Lead Manager. The funds raised will be strategically deployed to accelerate growth across the company's highest-performing channels, including inventory build to support large-scale U.S. wholesale supply contracts, sales, distribution and marketing expansion across Amazon USA, direct-to-consumer and Australian retail, as well as general working capital. This capital injection positions the company to further scale its rapidly expanding U.S. wholesale operations and strengthens its leadership position within the high-growth functional relaxation and alcohol alternative categories. The global kava extract market is estimated at US$1.6 billion (2024) and forecast to grow to US$5.6 billion by 2033, representing a CAGR of 14.1%, with the U.S. market experiencing even stronger growth driven by increasing consumer demand for functional relaxation products, alcohol alternatives, and natural sleep support solutions. The Calmer Co is strategically positioned to capture this structural consumer shift with its 15-year vertically integrated Pacific Island supply chain, proprietary CO2 extraction capability, and established retail partnerships.

With a scalable supply chain, increasing U.S. market share and structural tailwinds in the alcohol alternative category, the company believes it is entering a significant growth phase.